FY2025 EPS Estimates for Insulet Raised by Leerink Partnrs

Insulet Corporation (NASDAQ:PODD) – Leerink Partnrs lifted their FY2025 EPS estimates for shares of Insulet in a report issued on Tuesday, October 14th. Leerink Partnrs analyst M. Kratky now expects that the medical instruments supplier will post earnings of $4.62 per share for the year, up from their prior estimate of $4.61. The consensus estimate for Insulet’s current full-year earnings is $3.92 per share. Leerink Partnrs also issued estimates for Insulet’s FY2026 earnings at $6.03 EPS, FY2027 earnings at $7.72 EPS, FY2028 earnings at $9.60 EPS and FY2029 earnings at $11.55 EPS.

Other research analysts have also recently issued reports about the stock. Morgan Stanley reissued an “overweight” rating on shares of Insulet in a research report on Thursday, August 7th. Leerink Partners lifted their price target on shares of Insulet from $339.00 to $355.00 and gave the company an “outperform” rating in a research report on Tuesday. Piper Sandler lifted their price target on shares of Insulet from $320.00 to $360.00 and gave the company an “overweight” rating in a research report on Tuesday, September 16th. Jefferies Financial Group reissued a “buy” rating on shares of Insulet in a research report on Thursday, August 7th. Finally, Oppenheimer lifted their price target on shares of Insulet from $324.00 to $365.00 and gave the company an “outperform” rating in a research report on Monday, September 8th. Eighteen research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $348.05.

Insulet Trading Down 1.8%

Shares of PODD opened at $312.45 on Wednesday. The firm’s 50-day moving average price is $325.73 and its 200-day moving average price is $301.23. The firm has a market capitalization of $21.99 billion, a price-to-earnings ratio of 94.97, a PEG ratio of 2.66 and a beta of 1.40. The company has a current ratio of 2.26, a quick ratio of 1.81 and a debt-to-equity ratio of 0.64. Insulet has a 1-year low of $226.50 and a 1-year high of $353.50.

Insulet (NASDAQ:PODD) last announced its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share for the quarter, beating analysts’ consensus estimates of $0.92 by $0.25. The firm had revenue of $649.10 million for the quarter, compared to analyst estimates of $612.31 million. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The company’s revenue for the quarter was up 32.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.55 EPS. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS.

Insider Buying and Selling

In related news, SVP Prem Singh sold 687 shares of the company’s stock in a transaction on Monday, September 8th. The shares were sold at an average price of $347.49, for a total transaction of $238,725.63. Following the completion of the transaction, the senior vice president owned 3,456 shares in the company, valued at approximately $1,200,925.44. This represents a 16.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Laetitia Cousin sold 797 shares of the company’s stock in a transaction on Monday, September 8th. The stock was sold at an average price of $348.81, for a total transaction of $278,001.57. Following the transaction, the senior vice president owned 3,890 shares of the company’s stock, valued at approximately $1,356,870.90. This represents a 17.00% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.39% of the company’s stock.

Hedge Funds Weigh In On Insulet

Hedge funds and other institutional investors have recently modified their holdings of the stock. Zions Bancorporation National Association UT bought a new position in shares of Insulet during the first quarter worth $26,000. Larson Financial Group LLC boosted its position in shares of Insulet by 426.3% during the first quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier’s stock worth $26,000 after acquiring an additional 81 shares during the last quarter. Golden State Wealth Management LLC boosted its position in shares of Insulet by 202.9% during the second quarter. Golden State Wealth Management LLC now owns 103 shares of the medical instruments supplier’s stock worth $32,000 after acquiring an additional 69 shares during the last quarter. SouthState Corp boosted its position in shares of Insulet by 253.3% during the first quarter. SouthState Corp now owns 106 shares of the medical instruments supplier’s stock worth $28,000 after acquiring an additional 76 shares during the last quarter. Finally, Kozak & Associates Inc. bought a new position in Insulet during the second quarter valued at $32,000.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.